Manufacturer of Controlled Substances; Notice of Registration, 36483 [E7-12951]

Download as PDF 36483 Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12954 Filed 7–2–07; 8:45 am] DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Registration BILLING CODE 4410–09–P Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 8, 2007, Penick Corporation, 33 Industrial Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: By Notice dated March 19, 2007, and published in the Federal Register on March 27, 2007, (72 FR 14297), Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 15, 2007, Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Schedule Drug Schedule Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... II II II II II II II II II II II Drug Lysergic Acid Diethylamide (7315) Tetrahydrocannabinols (7370) ..... Alphamethadol (9605) .................. Phencyclidine (7471) .................... Ecgonine (9180) ........................... Methadone (9250) ........................ Morphine (9300) ........................... Schedule I I I II II II II The company plans to manufacture bulk products for finished dosage units and distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. The company plans to manufacture the listed controlled substances as bulk controlled substance intermediates for distribution to its customers for further manufacture or to manufacture pharmaceutical dosage forms. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007. The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Roche Diagnostics Operations, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Roche Diagnostics Operations, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12946 Filed 7–2–07; 8:45 am] Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12945 Filed 7–2–07; 8:45 am] Dated: June 26, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12951 Filed 7–2–07; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P BILLING CODE 4410–09–P jlentini on PROD1PC65 with NOTICES Gamma hydroxybutyric acid (2010). Amphetamine (1100) .................... Methylphenidate (1724) ................ VerDate Aug<31>2005 17:57 Jul 02, 2007 I II II Jkt 211001 PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 E:\FR\FM\03JYN1.SGM 03JYN1

Agencies

[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Page 36483]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12951]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated March 19, 2007, and published in the Federal 
Register on March 27, 2007, (72 FR 14297), Roche Diagnostics 
Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, 
Indianapolis, Indiana 46250, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Lysergic Acid Diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
Alphamethadol (9605).......................  I
Phencyclidine (7471).......................  II
Ecgonine (9180)............................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Roche Diagnostics Operations, Inc., to manufacture the listed basic 
class of controlled substance is consistent with the public interest at 
this time. DEA has investigated Roche Diagnostics Operations, Inc., to 
ensure that the company's registration is consistent with the public 
interest. The investigation has included inspection and testing of the 
company's physical security systems, verification of the company's 
compliance with state and local laws, and a review of the company's 
background and history. Therefore, pursuant to 21 U.S.C. 823, and in 
accordance with 21 CFR 1301.33, the above named company is granted 
registration as a bulk manufacturer of the basic class of controlled 
substance listed.

    Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-12951 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P